Delving into the Latest Updates on CR-3124 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

5-HT3 receptor

Mechanism

5-HT3 receptor antagonists(Serotonin 3 (5-HT3) receptor antagonists)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesDigestive System Disorders+ [2]

Active Indication-

Inactive Indication

FibromyalgiaInflammatory Bowel DiseasesNausea+ [1]

Originator Organization

Meda AB

Active Organization-

Inactive Organization

Meda AB

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Structure

Molecular FormulaC20H22N2O

InChIKeyRCJGTDKFZCRBAH-FVQHAEBGSA-N

CAS Registry263896-41-9

The physicochemical and biopharmaceutical properties, such as pK(a), crystal habit, water solubility, logD, molecular structure and dynamics, and membrane permeability of CR3124 (endo-2-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-1H-benz[e]isoindol-1-one, a novel potent 5-HT(3) receptor antagonist) have been studied in order to obtain preformulation information. The study showed that CR3124 is a very rigid molecule in which conformational freedom due to the presence of a rotatable bond is restricted by the interaction between an activated hydrogen and the amide oxygen and the conformation of the tropane piperidine ring is regulated by the environment in such a manner as to optimize the intermolecular interactions with the solvent. This chameleon behavior appears to be capable of explaining the biopharmaceutical properties showed by CR3124, such as low wettability, relatively good solubility, and very high membrane permeability.

100 Deals associated with CR-3124

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fibromyalgia	Preclinical	-	Meda AB	-
Inflammatory Bowel Diseases	Preclinical	-	Meda AB	-
Nausea	Preclinical	-	Meda AB	-
Substance-Related Disorders	Preclinical	-	Meda AB	-